| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 67028 |
Intravitreal injection of a pharmacologic agent |
14,345 |
10,790 |
$4.47M |
| J0178 |
Injection, aflibercept, 1 mg |
1,747 |
1,698 |
$4.38M |
| 92134 |
|
16,826 |
16,163 |
$573K |
| Q5128 |
Injection, ranibizumab-eqrn (cimerli), biosimilar, 0.1 mg |
479 |
342 |
$504K |
| J2778 |
Injection, ranibizumab, 0.1 mg |
444 |
427 |
$466K |
| 92250 |
|
5,734 |
5,607 |
$261K |
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
3,790 |
3,645 |
$257K |
| J9035 |
Injection, bevacizumab, 10 mg |
2,496 |
2,265 |
$253K |
| 92235 |
|
3,000 |
2,946 |
$243K |
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
5,023 |
4,912 |
$165K |
| 67228 |
|
69 |
67 |
$23K |
| 92014 |
Ophthalmological services: medical examination and evaluation, comprehensive, established patient |
504 |
489 |
$7K |
| 99204 |
Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity |
61 |
61 |
$5K |
| 99203 |
Office or other outpatient visit for the evaluation and management of a new patient, low complexity |
57 |
57 |
$5K |
| 76512 |
|
14 |
14 |
$734.25 |
| J7999 |
Compounded drug, not otherwise classified |
13 |
12 |
$77.51 |